VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

VERAXA Biotech AG has successfully completed its business combination with Voyager Acquisition Corp., marking its entry into the public markets on NASDAQ. The transaction, which closed on June 10, 2026, has resulted in VERAXA trading under the ticker symbols "VRXA" for its common stock and "VRXAW" for its warrants. While the specific deal value remains undisclosed, the transaction included a $27.5 million senior secured note financing and a $50 million share purchase agreement aimed at advancing VERAXA’s oncology pipeline.

Headquartered in Zurich, Switzerland, VERAXA Biotech AG is at the forefront of developing next-generation cancer therapies, particularly through its proprietary BiTAC platform. This innovative platform focuses on creating bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) designed to enhance therapeutic efficacy while minimizing side effects. The company's strategy centers on employing conditionally activated, AND-gated therapeutic approaches that target tumor cells with high specificity, thus preserving healthy cells. This dual-antigen targeting mechanism is particularly relevant for treating solid tumors, which represent a significant challenge in oncology.

The business combination with Voyager Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by Cantor Fitzgerald & Co., is expected to provide VERAXA with the necessary capital to accelerate its clinical development programs. The financing arrangements will enable the company to advance its BiTAC-TCE and BiTAC-ADC candidates through critical value inflection points. Recent presentations at the American Association for Cancer Research (AACR) Annual Meeting highlighted promising data from VERAXA’s BiTAC platform, reinforcing the potential of its pipeline to deliver improved safety and efficacy profiles compared to traditional therapies.

The completion of this business combination is significant not only for VERAXA but also for the broader biopharmaceutical sector, particularly in the field of oncology. As the demand for innovative cancer therapies continues to grow, companies like VERAXA that leverage advanced technologies such as bispecific TCEs and ADCs are well-positioned to capitalize on emerging market opportunities. The successful transition to a public company status is anticipated to enhance VERAXA's visibility and credibility within the investment community, potentially attracting further interest and investment.

In summary, the merger with Voyager Acquisition Corp. marks a pivotal moment for VERAXA Biotech AG as it embarks on its journey as a publicly traded entity. With a strong financial foundation and a promising pipeline, VERAXA aims to make significant strides in the development of next-generation cancer therapies, contributing to the evolving landscape of cancer treatment. The implications of this transaction extend beyond VERAXA, signaling a continued trend of SPACs playing a crucial role in financing innovative healthcare companies.